Original research article| Volume 84, ISSUE 6, P565-570, December 2011

Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)



      The efficacy of contraceptives is affected by its route and ease of administration. Herein, both pharmacokinetics and pharmacodynamics of the once-a-month combined injectable contraceptive medroxyprogesterone acetate (MPA) plus estradiol cypionate (E2-Cyp) were compared after intramuscular (IM) or subcutaneous (SC) injection in women of reproductive age.

      Study Design

      Thirty women were randomly assigned to the SC (n=15) or IM (n=15) route of MPA 25 mg+E2-Cyp 5 mg administration. Serum samples were obtained daily for 7 days and then three times a week for 40 days in order to quantify E2, progesterone and MPA. In addition, three ultrasounds were performed on each subject to determine follicular development, and a daily record of the bleeding pattern and side effects was maintained.


      A comparative analysis showed that the main pharmacokinetic (peak serum concentration, peak serum time, area under the serum concentration vs. time curve, absorption half-life and elimination half-life) and pharmacodynamic parameters, such as follicular development and ovulation, were similar in the SC vs. IM groups. Complete suppression in ovarian function was present in all women. The bleeding patterns and side effects were similar in both groups.


      The results presented herein demonstrate that the injection of 25 mg of MPA plus 5 mg of E2-Cyp has similar efficacy and safety with either the SC or IM route of administration. The SC option can be considered a viable self-administered contraceptive option that might increase women's compliance to contraceptive use.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Garza-Flores J.
        • Morales del Olmo A.
        • Fuziwara J.L.
        • et al.
        Introduction of Cyclofem once-a-month injectable contraceptive in Mexico.
        Contraception. 1998; 58: 7-12
        • Aedo A.R.
        • Landgren B.M.
        • Johannisson E.
        • et al.
        Pharmacokinetic and pharmacodynamic investigations with monthly contraceptive preparations.
        Contraception. 1985; 31: 453-469
        • Hall P.
        • Bahamondes L.
        • Diaz J.
        • Petta C.
        Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru.
        Contraception. 1997; 56: 353-359
        • Garza-Flores J.
        • Hall P.E.
        • Perez-Palacios G.
        Long-acting hormonal contraceptives for women.
        J Steroid Biochem Mol Biol. 1991; 40: 697-704
        • Bassol S.
        • Hernandez C.
        • Nava M.P.
        • Trujillo A.M.
        • Luz de la Cruz D.
        A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
        Contraception. 1995; 51: 307-311
        • Bassol S.
        • Garza-Flores J.
        Review of ovulation return upon discontinuation of once-a-month injectable contraceptives.
        Contraception. 1994; 49: 441-453
        • Roy G.
        Injectable contraception.
        Semin Reprod Med. 2010; 28: 126-132
        • Rowlands S.
        New technologies in contraception.
        BJOG. 2009; 116: 230-239
        • Kaunitz A.M.
        • Darney P.D.
        • Ross D.
        • Wolter K.D.
        • Speroff L.
        Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
        Contraception. 2009; 80: 7-17
        • Mohllajee A.P.
        • Curtis K.M.
        • Flanagan R.G.
        • et al.
        Keeping up with evidence a new system for WHO's evidence-based family planning guidance.
        Am J Prev Med. 2005; 28: 483-490
        • Out H.J.
        • Schnabel P.G.
        • Rombout F.
        • et al.
        A bioequivalence study of two urinary follicle stimulating hormone preparations: Follegon and Metrodin.
        Hum Reprod. 1995; 11: 61-63
        • Huisman J.A.M.
        • Paulussen R.J.A.
        • Geurts TBP Odink J.
        • Rekers H.
        Assessment of bioequivalence after subcutaneous and intramuscular administration of urinary gonadotrophins.
        Hum Reprod. 1997; 12: 34-38
        • Shrimanker K.
        • Saxena B.N.
        • Fotherby K.
        A radioimmunoassay for serum medroxyprogesterone acetate.
        J Steroid Biochem. 1978; 9: 359-363
        • Gerlinger C.
        • Endrikat J.
        • Kallischnigg G.
        • Wessel J.
        Evaluation of menstrual bleeding patterns: a new proposal for a universal guideline based on the analysis of more than 4500 bleeding diaries.
        Eur J Contracept Reprod Health Care. 2007; 12: 203-211
        • Kaunitz A.M.
        • Garceau R.J.
        • Cromie M.A.
        Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group.
        Contraception. 1999; 60: 179-187
        • Gallo M.F.
        • Grimes D.A.
        • Lopez L.M.
        • Schulz K.F.
        • d'Arcangues C.
        Combination injectable contraceptives for contraception.
        Cochrane Database Syst Rev. 2008; (Art. No.: CD004568)
        • Bahamondes L.
        • Marchi N.M.
        • Nakagava H.M.
        • et al.
        Self-administration with Uniject of the once-a-month injectable contraceptive Cyclofem.
        Contraception. 1997; 56: 301-304
        • Monastersky Maderas N.J.
        • Landau S.C.
        Pharmacy and clinic partnerships to expand access to injectable contraception.
        J Am Pharm Assoc. 2007; 47: 527-531
        • Lakha F.
        • Henderson C.
        • Glasier A.
        The acceptability of self-administration of subcutaneous Depo-Provera.
        Contraception. 2005; 72: 14-18
        • Prabhakaran S.
        Self-administration of injectable contraceptives.
        Contraception. 2008; 77: 315-317
        • Jain J.
        • Jakimiuk A.J.
        • Bode F.R.
        • Ross D.
        • Kaunitz A.M.
        Contraceptive efficacy and safety of DMPA-SC.
        Contraception. 2004; 70: 269-275
        • Pharmacia
        Lunelle (medroxyprogesterone acetate and estradiol cypionate) package insert.
        Kalamazoo, MI2001
        • Rahimy M.H.
        • Cromie M.A.
        • Hopkins N.K.
        • Tong D.M.
        Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics.
        Contraception. 1999; 60: 201-208
        • Fotherby K.
        • Koetsawang S.
        Metabolism of injectable formulations of contraceptive steroids in obese and thin women.
        Contraception. 1982; 26: 51-58
        • Jain J.
        • Dutton C.
        • Nicosia A.
        • Wajszczuk C.
        • Bode F.R.
        • Mishell Jr, D.R.
        Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.
        Contraception. 2004; 70: 11-18